Today: 7 February 2026
Subscribe

Shan Ahmed Khan

As a journalist focused on finance and the stock market, he delivers fast, reliable, and easy-to-understand coverage of market news.

CVS Health (CVS) Stock Soars in 2025 on New Guidance, AI Push and Clinic Reset – Is the Turnaround Finally Real?

CVS Health (CVS) Stock Soars in 2025 on New Guidance, AI Push and Clinic Reset – Is the Turnaround Finally Real?

New York / Hartford – December 10, 2025 – CVS Health Corporation (NYSE: CVS) is back in Wall Street’s good graces. After a bruising 2024, the stock has staged a powerful rebound in 2025 as management raised its 2025–2026 profit outlook, unveiled an AI‑native engagement platform, and tightened its primary‑care strategy. Shares were trading around $78 per share in midday trading on December 10, up roughly 2% on the day and around 75–80% year to date, far outpacing most large-cap healthcare peers. Reuters+2MarketWatch+2 With a market capitalization close to $100 billion, CVS has reasserted itself as one of the largest
10 December 2025
··
Pan American Silver Stock (PAAS) Hits 12‑Month High as Silver Breaks $60: What Today’s Rally Means for 2026

Pan American Silver Stock (PAAS) Hits 12‑Month High as Silver Breaks $60: What Today’s Rally Means for 2026

Pan American Silver Corp. (NYSE: PAAS; TSX: PAAS) is back in the spotlight. As of the morning of December 10, 2025, the stock is trading around $48–49 per share, after surging more than 11% on Tuesday and pushing to a new 12‑month high of $48.78 in today’s session.MarketBeat The move comes as silver smashes through $60 per ounce, gold holds above $4,200, and markets brace for a widely expected Federal Reserve rate cut at the December 9–10 FOMC meeting – a perfect macro backdrop for precious‑metals miners.FinancialContent+1 At the same time, Pan American is stacking company‑specific catalysts: Below is a
10 December 2025
··
BitMine Immersion Technologies Stock (BMNR) on December 10, 2025: Ethereum Mega‑Treasury, 50B‑Share Plan and High‑Risk 2026 Outlook

BitMine Immersion Technologies Stock (BMNR) on December 10, 2025: Ethereum Mega‑Treasury, 50B‑Share Plan and High‑Risk 2026 Outlook

BitMine Immersion Technologies (ticker BMNR) has turned into one of the loudest tickers in U.S. markets in late 2025. It’s no longer just a Bitcoin miner with immersion‑cooling hardware; it’s effectively an Ethereum super‑treasury with a public listing, options market, and even its own leveraged ETF ecosystem. StockAnalysis+1 As of the morning of December 10, 2025, BMNR sits at the crossroads of three big storylines: This article pulls together the latest news, forecasts and analyses available up to December 10, 2025, to give a grounded view of BitMine Immersion Technologies stock. It is informational only and not investment advice. 1.
10 December 2025
··
Biodexa Pharmaceuticals (NASDAQ: BDRX) Stock on December 10, 2025: Violent Rally, Phase 3 FAP Progress and What 2026 Might Hold

Biodexa Pharmaceuticals (NASDAQ: BDRX) Stock on December 10, 2025: Violent Rally, Phase 3 FAP Progress and What 2026 Might Hold

Biodexa Pharmaceuticals plc (NASDAQ: BDRX) has turned into one of the most volatile biotech tickers of late 2025. After a sharp multi‑day surge driven by retail trading interest and momentum headlines, the stock has whipsawed back down, even as the company advances a pivotal Phase 3 trial in a rare inherited cancer syndrome and lines up multiple new financing options. StockInvest+2MarketWatch+2 This article looks at where BDRX stock stands on December 10, 2025, the latest clinical and regulatory news from Biodexa, the company’s increasingly complex capital structure, and how third‑party models and analysts are framing the risk–reward profile into 2026.
10 December 2025
··
Abivax (ABVX) Stock Jumps on Eli Lilly Takeover Rumors: Latest News, Outlook and Forecasts – December 10, 2025

Abivax (ABVX) Stock Jumps on Eli Lilly Takeover Rumors: Latest News, Outlook and Forecasts – December 10, 2025

Abivax Société Anonyme (Euronext Paris: ABVX, Nasdaq: ABVX) is back in the spotlight on December 10, 2025, after its share price spiked again on fresh takeover speculation involving U.S. pharma giant Eli Lilly. The move caps an extraordinary year in which the French biotech has transformed from a relatively obscure name into a multibillion‑euro inflammatory bowel disease (IBD) contender.Reuters+1 Below is a detailed rundown of today’s news, the fundamental drivers, and the latest forecasts and analyses being published about Abivax. 1. Abivax stock today: how big is the move? On December 10, 2025, Abivax shares on Euronext Paris traded around
10 December 2025
····
JPMorgan Chase (JPM) Stock on December 10, 2025: Expense Shock, Dividend Update and Wall Street Forecasts

JPMorgan Chase (JPM) Stock on December 10, 2025: Expense Shock, Dividend Update and Wall Street Forecasts

JPMorgan Chase & Co. (NYSE: JPM) is back in the spotlight this week after a rare, sharp sell‑off triggered by new guidance on 2026 spending. At the same time, the bank has reaffirmed its hefty dividend and continues to draw mostly bullish long‑term forecasts from Wall Street. This article pulls together the key news, forecasts and analysis on JPM stock as of December 10, 2025, to help you understand what just happened, why the market is jumpy about expenses, and how analysts still think the story plays out. JPMorgan Chase stock today: price and recent performance As of late morning
10 December 2025
··
Newmont Stock Soars on Gold Rally: Latest NEM News, Analyst Forecasts and 2026 Outlook (10 December 2025)

Newmont Stock Soars on Gold Rally: Latest NEM News, Analyst Forecasts and 2026 Outlook (10 December 2025)

Newmont Corporation (NYSE: NEM) continues its spectacular run in 2025. On 10 December, the world’s largest gold miner’s share price climbed to about $94.09, up roughly 5.7% on the day and more than 130% year‑to‑date, as investors double down on the gold super‑cycle and Newmont’s aggressive restructuring and cost‑cutting program. Smartkarma Below is a deep dive into the latest news, forecasts and analyses dated 10 December 2025, plus the broader 2025 backdrop around earnings, restructuring and valuation debates that are driving NEM stock. Newmont Stock Today: Price, Momentum and Market Context As of mid‑day on 10 December 2025, Newmont trades
10 December 2025
··
Enveric Biosciences (ENVB) Stock Surges on Patent Win: News, Forecast & Analysis as of December 10, 2025

Enveric Biosciences (ENVB) Stock Surges on Patent Win: News, Forecast & Analysis as of December 10, 2025

Enveric Biosciences, Inc. (NASDAQ: ENVB) has suddenly jumped back onto traders’ screens. After closing regular trading on Tuesday, December 9, at about $5.92, the stock ripped more than 70% in after‑hours trading to around $10.29, driven by a fresh U.S. patent win for one of its key drug programs. Benzinga+2StockAnalysis+2 Pre‑market feeds early on December 10 show ENVB up roughly 77% to around $10.48 on StockAnalysis’ screener, while a separate live quote stream cited the name closer to $12.45, underlining just how chaotic price discovery is in this ultra‑thin micro‑cap. TechStock²+1 At the center of the move: a new Notice
10 December 2025
Oracle Stock Today: AI Bets, Debt Fears and What to Watch in Q2 FY26 Earnings

Oracle Stock Today: AI Bets, Debt Fears and What to Watch in Q2 FY26 Earnings

December 10, 2025 Oracle Corporation (NYSE: ORCL) heads into its fiscal Q2 2026 earnings report this evening positioned right at the intersection of two giant market narratives: the boom in generative AI infrastructure and the mounting concern that this boom is being built on a towering pile of debt. As of late morning trading, Oracle shares change hands around $221.53, modestly higher on the day and up roughly a third year-to-date, despite having surrendered the spectacular 36% one-day surge the stock logged after its last earnings report in September. Reuters Wall Street now sees tonight’s numbers as a crucial test
10 December 2025
····
Most Active Stocks Today: Nvidia, Tesla, PAVS, American Airlines and More Drive U.S. Market Volume on December 10, 2025

Most Active Stocks Today: Nvidia, Tesla, PAVS, American Airlines and More Drive U.S. Market Volume on December 10, 2025

The final U.S. trading days of 2025 are anything but sleepy. On Wednesday, December 10, 2025, the most active stocks today on the U.S. stock market span everything from mega‑cap AI leaders and streaming giants to ultra‑speculative penny stocks and battered turnaround stories. Below is a news‑style wrap that’s optimized for readers searching phrases like “most active stocks today,” “highest volume stocks,” “US stock market December 10 2025,” and specific tickers such as NVDA, TSLA, WBD, PAVS, AAL, HBAN, OPEN and more. Note: All prices and volumes are intraday as of December 10, 2025, based on public market data; this
10 December 2025
Biggest Stock Losers Today in the U.S. (Dec. 10, 2025): DYN, SLM, KTB, WAY and More Slide as Fed Decision Looms

Biggest Stock Losers Today in the U.S. (Dec. 10, 2025): DYN, SLM, KTB, WAY and More Slide as Fed Decision Looms

U.S. stocks are trading in a holding pattern on Wednesday, December 10, 2025, as Wall Street waits for the Federal Reserve’s final interest‑rate decision of the year. Index moves are modest, but beneath the surface a cluster of mid‑cap names is posting double‑digit percentage declines, led by Dyne Therapeutics (DYN), SLM Corp (SLM), Kontoor Brands (KTB) and Waystar Holding (WAY). Investing.com+1 According to real‑time data from StockScan, the 10 biggest U.S. stock losers today by percentage move (among actively traded listed shares) are: StockScan Below is a breakdown of what’s driving today’s biggest losers, plus how they fit into the
10 December 2025
···········
Top U.S. Stock Gainers Today (Dec. 10, 2025): ASPC, ENVB, BDRX, HSPO, BRZE Surge Ahead of Fed Decision

Top U.S. Stock Gainers Today (Dec. 10, 2025): ASPC, ENVB, BDRX, HSPO, BRZE Surge Ahead of Fed Decision

Published: December 10, 2025 — U.S. pre‑market sessionAll data and news current as of early U.S. trading hours on Dec. 10, 2025. Fed Day Starts Quiet for Indexes, Wild for Individual Stocks Wall Street is waking up to a classic “calm on the surface, chaos underneath” kind of Fed day. S&P 500, Nasdaq 100, Dow Jones and Russell 2000 futures are only fractionally lower or higher in pre‑market trading, with moves generally within a few tenths of a percent as investors wait for the Federal Reserve’s final rate decision of 2025.Yahoo Finance+3StockAnalysis+3Morningstar+3 Markets widely expect another 25‑basis‑point cut, but the
10 December 2025
··········
Aimei Health Technology (AFJK) Stock Rockets Over 1,000% After Merger Extension: Latest News, Risks and Outlook

Aimei Health Technology (AFJK) Stock Rockets Over 1,000% After Merger Extension: Latest News, Risks and Outlook

Updated December 10, 2025 Shares of Aimei Health Technology Co., Ltd. (NASDAQ: AFJK) have just delivered one of the wildest SPAC moves of 2025. On Tuesday, December 9, the blank‑check company’s stock exploded from a prior close of $8.00 to an intraday high of $98.15, closing at $88.50 — a one‑day gain of about 1,006% on nearly 6.7 million shares traded. StockAnalysis+1 Pre‑market and after‑hours trading then saw the price briefly slump into the mid‑$40s, before fresh volatility pushed real‑time quotes back toward the high‑$80s on December 10. Benzinga+1 The catalyst? Yet another extension of Aimei’s long‑running plan to merge
10 December 2025
··
GameStop (GME) Stock on December 10, 2025: Q3 Earnings Miss, Collectibles Boom and the Bitcoin Bet

GameStop (GME) Stock on December 10, 2025: Q3 Earnings Miss, Collectibles Boom and the Bitcoin Bet

GameStop Corp. (NYSE: GME) is back in the headlines after reporting fiscal Q3 2025 results on December 9. The video game retailer once synonymous with meme-stock manias is now trying to prove it can be a lean, consistently profitable specialty retailer while also managing a large Bitcoin position and a complex warrant dividend. As of late morning on December 10, 2025, GameStop shares trade around $23 per share, down roughly 1% from Tuesday’s close after initially falling about 5–6% in after-hours trading on the earnings release. Benzinga Below is a breakdown of what changed in GameStop’s latest quarter, how Wall
10 December 2025
···
Best Stocks to Buy Now (December 10, 2025): 8 U.S. Stocks Positioned for an AI‑Driven, Rate‑Cut Era

Best Stocks to Buy Now (December 10, 2025): 8 U.S. Stocks Positioned for an AI‑Driven, Rate‑Cut Era

The U.S. stock market is entering the last stretch of 2025 near record highs. The S&P 500 is up mid‑teens percent for the year and just closed slightly lower as investors wait for the Federal Reserve’s December 9–10 policy decision, with futures still pricing in a high probability of a 25‑basis‑point rate cut. Reuters+1 At the same time, the market is more concentrated than ever. J.P. Morgan estimates that AI‑linked companies have delivered roughly 75% of S&P 500 gains, 80% of earnings growth and 90% of capital spending growth since late 2022. J.P. Morgan Private Bank Oppenheimer now projects the
10 December 2025
···
US Stock Market Today, December 10, 2025: Wall Street Pauses Near Record Highs Ahead of Fed’s Final Rate Cut of the Year

US Stock Market Today, December 10, 2025: Wall Street Pauses Near Record Highs Ahead of Fed’s Final Rate Cut of the Year

US stock market trading on Wednesday, December 10, 2025, is all about one thing: the Federal Reserve. After a quiet, slightly negative session on Tuesday that left the S&P 500 just shy of its record high, index futures are drifting around the flat line as investors brace for the Fed’s final interest-rate decision of 2025.AP News+ 2Reuters+ 2 Markets have largely priced in a quarter‑point rate cut, but the real story is what comes next: how many cuts, if any, the Fed signals for 2026—and how Chair Jerome Powell frames that path in his press conference. That uncertainty is keeping
10 December 2025
··
GE Vernova (GEV) Stock Soars on New 2026 Outlook, Dividend Hike and $10 Billion Buyback

GE Vernova (GEV) Stock Soars on New 2026 Outlook, Dividend Hike and $10 Billion Buyback

Date: December 10, 2025 GE Vernova (NYSE: GEV) jumped after its 2025 Investor Update, where the energy technology company raised its 2026 and 2028 outlook, doubled its dividend, and expanded its buyback. Here’s what the latest guidance, analyst reactions and valuation signals mean for investors. GE Vernova stock today: price, performance and context GE Vernova Inc. (NYSE: GEV) is extending its remarkable run after its December 9 Investor Update in New York. On December 10, shares traded sharply higher in pre‑market and after‑hours sessions, at one point up 6–8%, after the company raised guidance, doubled its dividend and expanded its
10 December 2025
··
Fifth Third–Brex Deal Puts $5.6B AI-Powered Card Platform at Center of Comerica Merger Fight

Fifth Third–Brex Deal Puts $5.6B AI-Powered Card Platform at Center of Comerica Merger Fight

As Fifth Third Bank chooses Brex to power its commercial cards, the regional lender faces activist lawsuits and community protests over its planned Comerica acquisition. CINCINNATI / DALLAS / NEW YORK — December 10, 2025 Key Points Fifth Third turns to Brex for AI‑powered commercial cards On December 9, Fifth Third Bank announced a multi‑year partnership with Brex, under which the fintech will power the bank’s commercial card program across its commercial banking franchise. Fifth Third Bank+2Business Wire+2 According to the joint announcement, the deal: Fifth Third CEO and chair Tim Spence framed the move as a strategic bet on
10 December 2025
····
Robinhood (HOOD) Stock on December 10, 2025: 164% Rally, Indonesia Expansion and Insider Selling – Is It Still a Buy?

Robinhood (HOOD) Stock on December 10, 2025: 164% Rally, Indonesia Expansion and Insider Selling – Is It Still a Buy?

Robinhood Markets (NASDAQ: HOOD) is back in the spotlight on Wednesday, December 10, 2025, as the trading app’s shares hover in the mid‑$130s, not far below their 52‑week high of $153.86. Over the last 12 months, the stock has climbed roughly 164%, and it’s up nearly 270% year to date, turning Robinhood from a post‑meme punchline into one of the standout performers in the S&P 500 this year. Reuters+3Simply Wall St+3MarketBeat+3 That spectacular rally isn’t just hype. Robinhood’s turnaround is now backed by hard numbers: in the third quarter of 2025, total net revenue doubled year over year to $1.27
10 December 2025
GSK Stock on 10 December 2025: FDA Orphan-Drug Win, New Cancer Deal and What It Means for Investors

GSK Stock on 10 December 2025: FDA Orphan-Drug Win, New Cancer Deal and What It Means for Investors

GSK plc (LSE: GSK; NYSE: GSK) is ending 2025 in full “pipeline flex” mode. On 10 December 2025 the company announced fresh US regulatory momentum for an experimental lung cancer drug and a new oncology collaboration, while the share price sits near multi‑year highs after a year of strong earnings and upgraded guidance.Stock Titan+1 Below is a deep dive into today’s news, how GSK shares are trading, what analysts are forecasting, and where the risk/reward balance looks to be heading into 2026. This is information, not personalised investment advice. GSK share price today: still near the top of its 2025
10 December 2025
···
1 … 440 441 442 443 444 … 535

Stock Market Today

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

7 February 2026
Applied Digital Corporation shares jumped 25.52% Friday to $34.95, then slipped to $34.60 after hours. The company reported fiscal Q2 revenue up 250% to $126.6 million and signed leases for 600 MW of data center capacity in North Dakota. Applied Digital broke ground on a new 430‑MW campus in the southern U.S. in January. Financing includes a $100 million promissory note with 8% interest, paid in kind.
Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

7 February 2026
Eli Lilly shares rose 3.7% to $1,058.18 Friday after the FDA said it would act against telehealth firm Hims & Hers for marketing a $49 compounded weight-loss pill. The move followed a sharp selloff Thursday when Hims announced plans to sell a version of Novo Nordisk’s Wegovy. Investors remain uncertain how aggressively regulators will police copycat drugs and pricing in the obesity drug market.
Go toTop